Abstract 32P
Background
Worldwide breast cancer morbidity and mortality was still positioned in the top. Epidemiological data for breast cancer in Bali was not available although is essential for planning health measures. This study aimed to summarise the demographics of breast cancer subjects in Sanglah Genral Hospital from 2012-2019 and emphasize variables that related.
Methods
This is a descriptive study, collecting all breast cancer subjects data from January 2012 to 2019. All data from the cancer registry were analyzed and tabulated. Data were described as count and percentages. Reasoning analysis was done by looking at the counts from year to year. Information for counting age standardized rate was taken in national census data of population in Bali. Literature review if articles were also screened for the filtering out of the data regarding epidemiology of breast cancer in worldwide for comparison.
Results
A total of 1627 cases from 2012 to 2019 were included in this study for analysis. The incidence of breast cancer increase from 187 cases to 364 cases from 2013 to 2016. The age-standardized incidence rate was 84.33 per 100.000 women Balinese population. Most cases were found in advanced stages, stage IIIB (29.38%) and stage IV (22.56%). The most common tumor status found was T4 (49.78%), N1 (41.49%), and 22.5% were found to have metastasis. Lung metastasis dominated all the metastasis cases with the rate of 42.35%. Majority of histopathology subtypes in breast cancer subjects were invasive carcinoma of non special type (NST) (78.8%), followed by invasive lobular carcinoma (12.4%). From 1627 subjects, only 1160 (71.3%) had subtype tested, with luminal B subtype dominated the cases (36.5%).
Conclusions
Geographical and phenotypical variations differ from breast cancer subject epidemiology. Thus, statistical data should be done in each region for a better diagnosis and treatment care.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
196P - The tolerability and efficacy of FOLFIRINOX in gastro-oesophageal carcinoma
Presenter: Nicholas Travers
Session: Poster display session
Resources:
Abstract
197TiP - GLOW: Zolbetuximab + CAPOX compared with placebo + CAPOX as first-line treatment for patients with Claudin18.2+/HER2– Locally advanced unresectable or metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma: A randomized phase III study
Presenter: Rui-Hua Xu
Session: Poster display session
Resources:
Abstract
198TiP - SPOTLIGHT: Comparison of zolbetuximab or placebo + mFOLFOX6 as first-line treatment in patients with claudin18.2+/HER2– locally advanced unresectable or metastatic gastric or gastroesophageal junction adenocarcinoma (GEJ): A randomized phase III study
Presenter: Kensei Yamaguchi
Session: Poster display session
Resources:
Abstract
199TiP - Phase III (COSMIC-312) study of cabozantinib (C) in combination with atezolizumab (A) vs sorafenib (S) in patients (pts) with advanced hepatocellular carcinoma (aHCC) who have not received previous systemic anticancer therapy
Presenter: Thomas Yau
Session: Poster display session
Resources:
Abstract
200P - Apalutamide (APA) plus androgen deprivation therapy (ADT) for metastatic castration-sensitive prostate cancer (mCSPC): Analysis of pain and fatigue in the TITAN study
Presenter: Byung Ha Chung
Session: Poster display session
Resources:
Abstract
201P - Efficacy and safety of darolutamide in non-metastatic castration-resistant prostate cancer (nmCRPC) in the ARAMIS trial
Presenter: Jacob See-tong Pang
Session: Poster display session
Resources:
Abstract
202P - What is the best first-line therapy for metastatic castration-sensitive prostate cancer in 2019? A network meta-analysis
Presenter: Tsz Him So
Session: Poster display session
Resources:
Abstract
203P - Long term outcomes of 2-weekly docetaxel in metastatic high-volume hormone sensitive prostate cancer
Presenter: Suhas Singla
Session: Poster display session
Resources:
Abstract
204P - The effect of radium-223 therapy in agent orange related veterans with metastatic castrate resistance prostate carcinoma (CRPC)
Presenter: Andrew Liman
Session: Poster display session
Resources:
Abstract
205P - Treatment pattern and outcomes of radium-223 (Ra223) in metastatic castration resistant prostate cancer (mCRPC): Retrospective cohort analysis from Hong Kong
Presenter: Darren Poon
Session: Poster display session
Resources:
Abstract